Barely Significant
← all excerpts

Combined venetoclax and alvocidib in acute myeloid leukemia.

Oncotarget · 2017 · PMC5739808 · PMID 29291023

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
More specifically, while BIM knock-down showed a trend towards abrogating single-agent venetoclax activity, the change was not significant, suggesting that, at least in the two AML cell lines analyzed, single-agent venetoclax operates largely independent of BIM through the classic displacement model [ 49 ], whereby BCL-2 directly interacts with BAX/BAK to negatively regulate MOMP.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.